- Home
- M vs AKRO Comparison
M vs AKRO Comparison
Compare M & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | AKRO |
|---|---|---|
| Founded | 1830 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | M | AKRO |
|---|---|---|
| Price | $22.91 | $54.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 10 |
| Target Price | $19.80 | ★ $73.56 |
| AVG Volume (30 Days) | ★ 7.4M | 1.7M |
| Earning Date | 12-03-2025 | 11-07-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 178.61 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $22,712,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.76 | $21.34 |
| 52 Week High | $23.27 | $58.40 |
Technical Indicators
Market Signals| Indicator | M | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 70.17 | 66.54 |
| Support Level | $21.39 | $54.22 |
| Resistance Level | $23.27 | $54.70 |
| Average True Range (ATR) | 0.97 | 0.14 |
| MACD | 0.16 | -0.11 |
| Stochastic Oscillator | 90.75 | 64.18 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.